Adult hepatocellular carcinoma
MONDO:0016216Adult hepatocellular carcinoma is the most common primary liver cancer of adulthood. Derived from well-differentiated hepatocytes, it often develops from chronic liver cirrhosis which is most often due to hepatitis B and C virus or alcohol abuse. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.
Also known as: hepatocellular cancer, adult HCC, adult hepatocellular carcinoma, adult hepatoma, adult primary carcinoma of liver cell, adult primary carcinoma of the liver cell, adult primary hepatocellular carcinoma, adult primary hepatoma
2923 clinical trials for this condition and its sub-types, 12 tagged with Adult hepatocellular carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Radiation zaps liver tumors in patients too sick for surgery
Disease control CompletedThis pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…
Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Two-Drug cocktail shows promise against tough liver cancer
Disease control CompletedThis study tested a combination of two drugs—sorafenib (a targeted therapy) and pembrolizumab (an immunotherapy)—in 37 people with advanced liver cancer that had spread. The goal was to see if the combo could shrink tumors and help people live longer. The trial was early-stage, s…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Radiation plus drug may boost survival in advanced liver cancer
Disease control CompletedThis phase 3 trial tested whether adding focused radiation (SBRT) to the drug sorafenib helps people with advanced liver cancer live longer compared to sorafenib alone. The study enrolled 193 adults with liver cancer that could not be surgically removed. Researchers measured over…
Phase 3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Tough-to-Treat liver cancer
Disease control CompletedThis study tested a combination of two drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but whose cancer worsened after other treatments. The goal was to see if the combination could shrink tumors or control the d…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC